Case Studies2020-11-19T22:10:23-08:00

Case Studies

Cannabis in Psychedelic Therapy: Potential and Precautions

LOS ANGELES- The integration of cannabis into psychedelic-assisted psychotherapy is gaining attention as a potential treatment for various mental health conditions, including post-traumatic stress disorder (PTSD), depression, and anxiety. This approach involves administering cannabis in ...

Cybin Partners with Thermo Fisher for U.S. Manufacturing

LOS ANGELES- Cybin Inc. a neuropsychiatry company, has announced a collaboration with Thermo Fisher Scientific to support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, its proprietary deuterated psilocin analog, for the ...

Rubicon Organics Appoints Glen Ibbott as Interim CFO

LOS ANGELES- Rubicon Organics Inc.  a Canadian producer of certified organic cannabis products, has appointed Glen Ibbott as Interim Chief Financial Officer, effective May 15, 2025. This leadership change follows the departure of Janis Risbin ...

TILT Holdings Reports First Quarter 2025 Financial Results

LOS ANGELES- TILT Holdings Inc. announced its financial results for the first quarter ended March 31, 2025, reflecting a year-over-year revenue decline and continued strategic realignment towards its Jupiter inhalation technology business. Financial Performance The ...

Cresco Labs Reports First Quarter Financial Performance

LOS ANGELES- Cresco Labs reported first-quarter revenues of $184 million, reflecting the company’s growth trajectory in the competitive cannabis market. This increase in revenue is attributed to market expansion and enhanced product offerings under its ...

Ohio to Award Dual-Use Cannabis Licenses by June

LOS ANGELES- Ohio is set to begin the transition to allow existing medical cannabis dispensaries to sell cannabis recreationally. The state's Joint Committee on Agency Rule Review has approved regulations for dual-use licenses, with applications ...

A Delays Hearing on Psychedelic Compounds

LOS ANGELES- The Drug Enforcement Administration (DEA) has postponed a crucial administrative hearing originally scheduled for June on the proposed ban of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). This decision follows a legal ...

Subscribe To Our Newsletter

Go to Top